These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18349472)

  • 21. Nephrogenic systemic fibrosis: history and epidemiology.
    Thomsen HS
    Radiol Clin North Am; 2009 Sep; 47(5):827-31, vi. PubMed ID: 19744597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link?
    Perazella MA
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):200-2. PubMed ID: 17699407
    [No Abstract]   [Full Text] [Related]  

  • 23. Gadolinium and kidney disease: are your patients at risk?
    Hollister D
    Nephrol Nurs J; 2008; 35(2):196-7. PubMed ID: 18472687
    [No Abstract]   [Full Text] [Related]  

  • 24. Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide.
    Leiner T; Herborn CU; Goyen M
    Eur Radiol; 2007 Aug; 17(8):1921-3. PubMed ID: 17458550
    [No Abstract]   [Full Text] [Related]  

  • 25. The need for radiologists' awareness of nephrogenic systemic fibrosis.
    Aydingöz U
    Diagn Interv Radiol; 2006 Dec; 12(4):161-2. PubMed ID: 17160795
    [No Abstract]   [Full Text] [Related]  

  • 26. Nephrogenic systemic fibrosis in Japan: advisability of keeping the administered dose as low as possible.
    Tsushima Y; Takahashi-Taketomi A; Endo K
    Radiology; 2008 Jun; 247(3):915-6. PubMed ID: 18487548
    [No Abstract]   [Full Text] [Related]  

  • 27. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
    Broome DR
    Eur J Radiol; 2008 May; 66(2):230-4. PubMed ID: 18372138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gadolinium-associated nephrogenic systemic fibrosis.
    Schlaudecker JD; Bernheisel CR
    Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal failure and gadolinium. The number of documented cases is rising.
    Prescrire Int; 2008 Oct; 17(97):205. PubMed ID: 19537311
    [No Abstract]   [Full Text] [Related]  

  • 30. [Nephrogenic systemic fibrosis].
    Breitschaft A; Stahlmann R
    Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nephrogenic systemic fibrosis: late skin manifestations.
    Bangsgaard N; Marckmann P; Rossen K; Skov L
    Arch Dermatol; 2009 Feb; 145(2):183-7. PubMed ID: 19221265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gadolinium and nephrogenic systemic fibrosis: time to tighten practice.
    Mendichovszky IA; Marks SD; Simcock CM; Olsen OE
    Pediatr Radiol; 2008 May; 38(5):489-96; quiz 602-3. PubMed ID: 17943276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacovigilance: what to do if you see an adverse reaction and the consequences.
    Stenver DI
    Eur J Radiol; 2008 May; 66(2):184-6. PubMed ID: 18372136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis.
    Abraham JL; Thakral C
    Eur J Radiol; 2008 May; 66(2):200-7. PubMed ID: 18374532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute phase reaction to gadolinium-DTPA in dialysis patients.
    Steen H; Giannitsis E; Sommerer C; Bahner U; Brandl M; Merbach C; Merten C; Ritz E; Katus HA; Zeier M; Schwenger V
    Nephrol Dial Transplant; 2009 Apr; 24(4):1274-7. PubMed ID: 19042926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Possibly enhanced Gd excretion in dialysate, but no major clinical benefit of 3-5 months of treatment with sodium thiosulfate in late stages of nephrogenic systemic fibrosis.
    Marckmann P; Nielsen AH; Sloth JJ
    Nephrol Dial Transplant; 2008 Oct; 23(10):3280-2. PubMed ID: 18436563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current status of gadolinium toxicity in patients with kidney disease.
    Perazella MA
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):461-9. PubMed ID: 19201920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MRI gadolinium-based contrast agents. Radiologists beware!
    Goullé JP; Cattanéo A; Saussereau E; Mahieu L; Guerbet M; Lacroix C
    Ann Pharm Fr; 2009 Sep; 67(5):335-9. PubMed ID: 19695369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand.
    Sieber MA; Lengsfeld P; Walter J; Schirmer H; Frenzel T; Siegmund F; Weinmann HJ; Pietsch H
    J Magn Reson Imaging; 2008 May; 27(5):955-62. PubMed ID: 18425843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gadolinium chelate-associated nephrogenic systemic fibrosis.
    Kei PL; Chan LP
    Singapore Med J; 2008 Mar; 49(3):181-5. PubMed ID: 18362996
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.